Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci
Authors:
- Michael J. DowzickyMDMichael J. Dowzicky
- Ronald N. JonesRJRonald N. Jones
- 31 March 2007
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 57 (3) , 333-336
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Viridans Streptococci Isolated by Culture from Blood of Cancer Patients: Clinical and Microbiologic Analysis of 50 CasesJournal of Clinical Microbiology, 2006
- In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin AmericaThe Brazilian Journal of Infectious Diseases, 2005
- Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004)Diagnostic Microbiology and Infectious Disease, 2005
- In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae : Mechanisms of Macrolide and Tetracycline ResistanceAntimicrobial Agents and Chemotherapy, 2004
- In Vitro Activities of Tigecycline (GAR-936) against Multidrug-Resistant Staphylococcus aureus and Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2004
- In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptidesJournal of Antimicrobial Chemotherapy, 2003
- In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in SpainAntimicrobial Agents and Chemotherapy, 2002
- Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin AmericaClinical Microbiology and Infection, 2001
- In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive BacteriaAntimicrobial Agents and Chemotherapy, 2000
- Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolatesDiagnostic Microbiology and Infectious Disease, 2000